Boston, MA – October 9, 2018 – Cerevance, a clinical-stage drug discovery and development company focused on brain diseases, today announced that it has appointed Ted Hibben as Chief Business Officer. A twenty-year biotechnology industry veteran, Mr. Hibben has formed over $2 billion in platform and product-based R&D collaborations.
Prior to joining Cerevance, Mr. Hibben served as Chief Business Officer at Catabasis where he led partnering activities. Before Catabasis, he was Senior Vice President of Ensemble Therapeutics where he formed multi-year, multi-target discovery and development-stage collaborations. His experience also includes serving as Chief Business Officer at the RNAi product platform company, Cequent Pharmaceuticals, and as Vice President of Business Development and Alliance Management at the immunomodulatory company, Coley Pharmaceutical Group, where he orchestrated nine development alliances.
“We’re looking forward to having Ted’s leadership in identifying, structuring and negotiating creative partnerships with pharmaceutical and biotechnology companies that will provide critical validation of our technology platform and execution ability,” said Brad Margus, CEO of Cerevance. “As our discovery platform has begun yielding novel targets and our lead compounds advance through clinical development, his strategic partnering expertise will be critical.”
Mr. Hibben earned his M.B.A. from Harvard University and his A.B. from Dartmouth College. Throughout his career, he has been involved with external and in-house programs ranging from discovery through Phase 3 in therapeutic areas spanning a full range of modalities including biologics, small molecules and vaccines.
“Patients with neurological and psychiatric diseases are desperate for better treatments, and our industry urgently needs new CNS targets to pursue,” said Mr. Hibben. “I’m looking forward to working with the Cerevance team to form strategic partnerships that will harness the company’s unique capability to solve these problems.”
Cerevance is a private pharmaceutical company focused on central nervous system diseases. The company’s strengths include its powerful NETSseq target discovery platform, a pipeline of novel discovery-stage and clinical-stage compounds and a proven team. Its scientists believe that they are well positioned to deliver life-changing therapeutics for patients who have brain-related disorders. For additional information, please visit www.cerevance.com.
Robert Middlebrook, +1-408-220-5722